Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Non Operating Income (2016 - 2025)

Karyopharm Therapeutics' Non Operating Income history spans 13 years, with the latest figure at -$10.0 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 199.31% year-over-year to -$10.0 million; the TTM value through Dec 2025 reached -$10.3 million, down 119.51%, while the annual FY2025 figure was $152000.0, 99.46% down from the prior year.
  • Non Operating Income reached -$10.0 million in Q4 2025 per KPTI's latest filing, up from -$17.9 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $52.0 million in Q2 2024 to a low of -$17.9 million in Q3 2025.
  • Average Non Operating Income over 5 years is $1.7 million, with a median of -$3.1 million recorded in 2023.
  • Peak YoY movement for Non Operating Income: tumbled 20312.5% in 2023, then soared 1874.03% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$8.4 million in 2021, then skyrocketed by 316.11% to $18.1 million in 2022, then plummeted by 50.31% to $9.0 million in 2023, then grew by 12.62% to $10.1 million in 2024, then tumbled by 199.31% to -$10.0 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Non Operating Income are -$10.0 million (Q4 2025), -$17.9 million (Q3 2025), and -$2.2 million (Q2 2025).